The high level of unmet need for iron deficiency therapy worldwide suggest a wealth of opportunities for rapid growth with the right product
The business opportunity
It is an essential part of iron4u’s philosophy to create a company where all employees, health care professionals and partners worldwide join forces in a respectful, loyal and constructive cooperation.
Iron4u aim to establish effective relations based on trust and mutual respect, in order to create strong networks that in accordance with our ethical code of conduct will thrive towards eradication of iron deficiency and iron deficiency anaemia among patients and in the general population.
Our market analyses indicate that the commercial potential for a truly effective and well-tolerated IV iron treatment is enormous. Intravenous iron sales in the US alone are set to reach $1 billion in 2019. In the longer term, the US market could be worth more than $5 billion. The high levels of unmet need for iron deficiency therapy worldwide suggest a wealth of opportunities for rapid growth with the right product.
We also want to make sure that ferric bepectate is available across a broad spectrum of unmet needs. That includes the challenges of treating iron deficiency in children, which can have serious long-term consequences for growth, development and immunity to infection.
In this respect, we achieved an important milestone on 1 December 2017, when the European Medicines Agency (EMA) agreed to our pediatric investigation plan (PIP) to study ferric bepectate in patients aged 6 months to 18 years. We recently published the results of our Phase II clinical trials in adults, which confirmed ferric bepectate’s highly attractive product profile.